Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)

Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Depart...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Khalifa E. Sharquie [verfasserIn] Adil A. Noaimi [verfasserIn] Ahmed G. Al-Ghazzi [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2015

Schlagwörter:	Cutaneous leishmaniasis Podophyllin Treatment

Übergeordnetes Werk:	In: Journal of Dermatology and Dermatologic Surgery - Wolters Kluwer Medknow Publications, 2016, 19(2015), 2, Seite 108-113
Übergeordnetes Werk:	volume:19 ; year:2015 ; number:2 ; pages:108-113

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.jdds.2014.10.001

Katalog-ID:	DOAJ048773034

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ048773034
003	DE-627
005	20230308135940.0
007	cr uuu---uuuuu
008	230227s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.jdds.2014.10.001 \|2 doi
035			\|a (DE-627)DOAJ048773034
035			\|a (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RL1-803
100	0		\|a Khalifa E. Sharquie \|e verfasserin \|4 aut
245	1	0	\|a Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.
650		4	\|a Cutaneous leishmaniasis
650		4	\|a Podophyllin
650		4	\|a Treatment
653		0	\|a Dermatology
700	0		\|a Adil A. Noaimi \|e verfasserin \|4 aut
700	0		\|a Ahmed G. Al-Ghazzi \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Dermatology and Dermatologic Surgery \|d Wolters Kluwer Medknow Publications, 2016 \|g 19(2015), 2, Seite 108-113 \|w (DE-627)797382100 \|w (DE-600)2785542-9 \|x 23522429 \|7 nnns
773	1	8	\|g volume:19 \|g year:2015 \|g number:2 \|g pages:108-113
856	4	0	\|u https://doi.org/10.1016/j.jdds.2014.10.001 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S2352241015000171 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2352-2410 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 19 \|j 2015 \|e 2 \|h 108-113

Indexfelder

author_variant	k e s kes a a n aan a g a g agag
matchkey_str	article:23522429:2015----::ramnoctnosesmnaibtpcl5oohlisltosnlbid
hierarchy_sort_str	2015
callnumber-subject-code	RL
publishDate	2015
allfields	10.1016/j.jdds.2014.10.001 doi (DE-627)DOAJ048773034 (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3 DE-627 ger DE-627 rakwb eng RL1-803 Khalifa E. Sharquie verfasserin aut Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects. Cutaneous leishmaniasis Podophyllin Treatment Dermatology Adil A. Noaimi verfasserin aut Ahmed G. Al-Ghazzi verfasserin aut In Journal of Dermatology and Dermatologic Surgery Wolters Kluwer Medknow Publications, 2016 19(2015), 2, Seite 108-113 (DE-627)797382100 (DE-600)2785542-9 23522429 nnns volume:19 year:2015 number:2 pages:108-113 https://doi.org/10.1016/j.jdds.2014.10.001 kostenfrei https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 kostenfrei http://www.sciencedirect.com/science/article/pii/S2352241015000171 kostenfrei https://doaj.org/toc/2352-2410 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 19 2015 2 108-113
spelling	10.1016/j.jdds.2014.10.001 doi (DE-627)DOAJ048773034 (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3 DE-627 ger DE-627 rakwb eng RL1-803 Khalifa E. Sharquie verfasserin aut Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects. Cutaneous leishmaniasis Podophyllin Treatment Dermatology Adil A. Noaimi verfasserin aut Ahmed G. Al-Ghazzi verfasserin aut In Journal of Dermatology and Dermatologic Surgery Wolters Kluwer Medknow Publications, 2016 19(2015), 2, Seite 108-113 (DE-627)797382100 (DE-600)2785542-9 23522429 nnns volume:19 year:2015 number:2 pages:108-113 https://doi.org/10.1016/j.jdds.2014.10.001 kostenfrei https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 kostenfrei http://www.sciencedirect.com/science/article/pii/S2352241015000171 kostenfrei https://doaj.org/toc/2352-2410 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 19 2015 2 108-113
allfields_unstemmed	10.1016/j.jdds.2014.10.001 doi (DE-627)DOAJ048773034 (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3 DE-627 ger DE-627 rakwb eng RL1-803 Khalifa E. Sharquie verfasserin aut Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects. Cutaneous leishmaniasis Podophyllin Treatment Dermatology Adil A. Noaimi verfasserin aut Ahmed G. Al-Ghazzi verfasserin aut In Journal of Dermatology and Dermatologic Surgery Wolters Kluwer Medknow Publications, 2016 19(2015), 2, Seite 108-113 (DE-627)797382100 (DE-600)2785542-9 23522429 nnns volume:19 year:2015 number:2 pages:108-113 https://doi.org/10.1016/j.jdds.2014.10.001 kostenfrei https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 kostenfrei http://www.sciencedirect.com/science/article/pii/S2352241015000171 kostenfrei https://doaj.org/toc/2352-2410 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 19 2015 2 108-113
allfieldsGer	10.1016/j.jdds.2014.10.001 doi (DE-627)DOAJ048773034 (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3 DE-627 ger DE-627 rakwb eng RL1-803 Khalifa E. Sharquie verfasserin aut Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects. Cutaneous leishmaniasis Podophyllin Treatment Dermatology Adil A. Noaimi verfasserin aut Ahmed G. Al-Ghazzi verfasserin aut In Journal of Dermatology and Dermatologic Surgery Wolters Kluwer Medknow Publications, 2016 19(2015), 2, Seite 108-113 (DE-627)797382100 (DE-600)2785542-9 23522429 nnns volume:19 year:2015 number:2 pages:108-113 https://doi.org/10.1016/j.jdds.2014.10.001 kostenfrei https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 kostenfrei http://www.sciencedirect.com/science/article/pii/S2352241015000171 kostenfrei https://doaj.org/toc/2352-2410 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 19 2015 2 108-113
allfieldsSound	10.1016/j.jdds.2014.10.001 doi (DE-627)DOAJ048773034 (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3 DE-627 ger DE-627 rakwb eng RL1-803 Khalifa E. Sharquie verfasserin aut Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects. Cutaneous leishmaniasis Podophyllin Treatment Dermatology Adil A. Noaimi verfasserin aut Ahmed G. Al-Ghazzi verfasserin aut In Journal of Dermatology and Dermatologic Surgery Wolters Kluwer Medknow Publications, 2016 19(2015), 2, Seite 108-113 (DE-627)797382100 (DE-600)2785542-9 23522429 nnns volume:19 year:2015 number:2 pages:108-113 https://doi.org/10.1016/j.jdds.2014.10.001 kostenfrei https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 kostenfrei http://www.sciencedirect.com/science/article/pii/S2352241015000171 kostenfrei https://doaj.org/toc/2352-2410 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 19 2015 2 108-113
language	English
source	In Journal of Dermatology and Dermatologic Surgery 19(2015), 2, Seite 108-113 volume:19 year:2015 number:2 pages:108-113
sourceStr	In Journal of Dermatology and Dermatologic Surgery 19(2015), 2, Seite 108-113 volume:19 year:2015 number:2 pages:108-113
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Cutaneous leishmaniasis Podophyllin Treatment Dermatology
isfreeaccess_bool	true
container_title	Journal of Dermatology and Dermatologic Surgery
authorswithroles_txt_mv	Khalifa E. Sharquie @@aut@@ Adil A. Noaimi @@aut@@ Ahmed G. Al-Ghazzi @@aut@@
publishDateDaySort_date	2015-01-01T00:00:00Z
hierarchy_top_id	797382100
id	DOAJ048773034
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048773034</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308135940.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jdds.2014.10.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048773034</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Khalifa E. Sharquie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cutaneous leishmaniasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Podophyllin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adil A. Noaimi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmed G. Al-Ghazzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Dermatology and Dermatologic Surgery</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2016</subfield><subfield code="g">19(2015), 2, Seite 108-113</subfield><subfield code="w">(DE-627)797382100</subfield><subfield code="w">(DE-600)2785542-9</subfield><subfield code="x">23522429</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:108-113</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jdds.2014.10.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2352241015000171</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2352-2410</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">108-113</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Khalifa E. Sharquie
spellingShingle	Khalifa E. Sharquie misc RL1-803 misc Cutaneous leishmaniasis misc Podophyllin misc Treatment misc Dermatology Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
authorStr	Khalifa E. Sharquie
ppnlink_with_tag_str_mv	@@773@@(DE-627)797382100
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RL1-803
illustrated	Not Illustrated
issn	23522429
topic_title	RL1-803 Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) Cutaneous leishmaniasis Podophyllin Treatment
topic	misc RL1-803 misc Cutaneous leishmaniasis misc Podophyllin misc Treatment misc Dermatology
topic_unstemmed	misc RL1-803 misc Cutaneous leishmaniasis misc Podophyllin misc Treatment misc Dermatology
topic_browse	misc RL1-803 misc Cutaneous leishmaniasis misc Podophyllin misc Treatment misc Dermatology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Dermatology and Dermatologic Surgery
hierarchy_parent_id	797382100
hierarchy_top_title	Journal of Dermatology and Dermatologic Surgery
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)797382100 (DE-600)2785542-9
title	Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
ctrlnum	(DE-627)DOAJ048773034 (DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3
title_full	Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
author_sort	Khalifa E. Sharquie
journal	Journal of Dermatology and Dermatologic Surgery
journalStr	Journal of Dermatology and Dermatologic Surgery
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
container_start_page	108
author_browse	Khalifa E. Sharquie Adil A. Noaimi Ahmed G. Al-Ghazzi
container_volume	19
class	RL1-803
format_se	Elektronische Aufsätze
author-letter	Khalifa E. Sharquie
doi_str_mv	10.1016/j.jdds.2014.10.001
author2-role	verfasserin
title_sort	treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
callnumber	RL1-803
title_auth	Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
abstract	Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.
abstractGer	Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.
abstract_unstemmed	Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
url	https://doi.org/10.1016/j.jdds.2014.10.001 https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3 http://www.sciencedirect.com/science/article/pii/S2352241015000171 https://doaj.org/toc/2352-2410
remote_bool	true
author2	Adil A. Noaimi Ahmed G. Al-Ghazzi
author2Str	Adil A. Noaimi Ahmed G. Al-Ghazzi
ppnlink	797382100
callnumber-subject	RL - Dermatology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.jdds.2014.10.001
callnumber-a	RL1-803
up_date	2024-07-03T19:36:35.746Z
_version_	1803587835131854848
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048773034</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308135940.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jdds.2014.10.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048773034</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe72d694c7a3e4538b7fbb5683534a8c3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Khalifa E. Sharquie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cutaneous leishmaniasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Podophyllin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adil A. Noaimi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmed G. Al-Ghazzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Dermatology and Dermatologic Surgery</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2016</subfield><subfield code="g">19(2015), 2, Seite 108-113</subfield><subfield code="w">(DE-627)797382100</subfield><subfield code="w">(DE-600)2785542-9</subfield><subfield code="x">23522429</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:108-113</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jdds.2014.10.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e72d694c7a3e4538b7fbb5683534a8c3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2352241015000171</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2352-2410</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">108-113</subfield></datafield></record></collection>
score	7.402895

Nicht das Richtige dabei?

Schreiben Sie uns!

Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?